[go: up one dir, main page]

WO2013054147A3 - Erlotinib salts - Google Patents

Erlotinib salts Download PDF

Info

Publication number
WO2013054147A3
WO2013054147A3 PCT/HU2012/000102 HU2012000102W WO2013054147A3 WO 2013054147 A3 WO2013054147 A3 WO 2013054147A3 HU 2012000102 W HU2012000102 W HU 2012000102W WO 2013054147 A3 WO2013054147 A3 WO 2013054147A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid salt
erlotinib
erlotinib salts
mandelic
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2012/000102
Other languages
French (fr)
Other versions
WO2013054147A2 (en
Inventor
Ede MÁRVÁNYOS
Gábor NÉMETH
Balázs VOLK
László Pongó
József Barkóczy
András DANCSÓ
Mónika MEZŐVÁRI
Zoltán VARGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Pharmaceuticals PLC filed Critical Egis Pharmaceuticals PLC
Priority to BR112014008733A priority Critical patent/BR112014008733A2/en
Priority to EP12826647.5A priority patent/EP2776406A2/en
Priority to EA201490773A priority patent/EA201490773A1/en
Priority to CN201280058335.8A priority patent/CN103958483A/en
Publication of WO2013054147A2 publication Critical patent/WO2013054147A2/en
Publication of WO2013054147A3 publication Critical patent/WO2013054147A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to erlotinib salts selected from the group consisting of the maleic acid salt, salicylic acid salt. L-mandelic acid alt. adipinic acid salt. 1.5-naphthalene-disulfonic acid salt. L-pyroglutamic acid salt. 1 -hydroxy-2-naphthoic acid salt, and mandelic acid salt and amorphous and crystalline forms, hydrates and solvates thereof. The erlotinib salts of the present invention are useful in therapy, particularly for the treatment or prophylaxis of non- small cell lung carcinoma and pancreas rarcinoma.
PCT/HU2012/000102 2011-10-10 2012-10-10 Erlotinib salts Ceased WO2013054147A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BR112014008733A BR112014008733A2 (en) 2011-10-10 2012-10-10 erlotinib salts
EP12826647.5A EP2776406A2 (en) 2011-10-10 2012-10-10 Erlotinib salts
EA201490773A EA201490773A1 (en) 2011-10-10 2012-10-10 EXTRACTIONS OF EXPOSURE
CN201280058335.8A CN103958483A (en) 2011-10-10 2012-10-10 Erlotinib salts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1100562 2011-10-10
HU1100562A HU230483B1 (en) 2011-10-10 2011-10-10 Erlotinib salts

Publications (2)

Publication Number Publication Date
WO2013054147A2 WO2013054147A2 (en) 2013-04-18
WO2013054147A3 true WO2013054147A3 (en) 2013-06-13

Family

ID=89990469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2012/000102 Ceased WO2013054147A2 (en) 2011-10-10 2012-10-10 Erlotinib salts

Country Status (6)

Country Link
EP (1) EP2776406A2 (en)
CN (1) CN103958483A (en)
BR (1) BR112014008733A2 (en)
EA (1) EA201490773A1 (en)
HU (1) HU230483B1 (en)
WO (1) WO2013054147A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118737A1 (en) * 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CN104250230A (en) * 2014-09-05 2014-12-31 亿腾药业（泰州）有限公司 Erlotinib citrate, crystal form and preparation method of two
CN116554111B (en) * 2023-03-09 2025-09-12 湖北中医药大学 A co-amorphous form of erlotinib and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060691A2 (en) * 2005-11-23 2007-05-31 Natco Pharma Limited A novel process for the preparation of erlotinib
WO2010109443A1 (en) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011068403A2 (en) * 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69536015D1 (en) 1995-03-30 2009-12-10 Pfizer Prod Inc Quinazolinone derivatives
MXPA00010610A (en) 1998-04-29 2002-07-02 Osi Pharm Inc N-(3-ethynylphenylamino)- 6,7-bis(2- methoxyethoxy) -4-quinazolinamine mesylate anhydrate and monohydrate.
KR20140069232A (en) 2007-04-04 2014-06-09 시플라 리미티드 Process for preparation of erlotinib and its pharmaceutically acceptable salts

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060691A2 (en) * 2005-11-23 2007-05-31 Natco Pharma Limited A novel process for the preparation of erlotinib
WO2010109443A1 (en) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011068403A2 (en) * 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts

Also Published As

Publication number Publication date
EP2776406A2 (en) 2014-09-17
CN103958483A (en) 2014-07-30
BR112014008733A2 (en) 2017-04-25
HU230483B1 (en) 2016-07-28
WO2013054147A2 (en) 2013-04-18
EA201490773A1 (en) 2014-10-30
HUP1100562A2 (en) 2013-05-28

Similar Documents

Publication Publication Date Title
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MX2020009397A (en) Compositions and methods for inhibition of the jak pathway.
MD20170016A2 (en) Aminopyrimidinyl compounds as JAK inhibitors
WO2011133795A3 (en) Beta-carbolines as inhibitors of haspin and dyrk kinases
PH12014500103A1 (en) Pyridin-2(1h)-one derivatives as jak inhibitors
TN2015000121A1 (en) Gdf-8 inhibitors
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2012017239A3 (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
ZA201500326B (en) Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
WO2012104007A3 (en) 7-azaindole derivatives
MX395263B (en) Free-base crystalline form of lorlatinib
HK1210174A1 (en) Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
MX355088B (en) Thienopyrimidine inhibitors of atypical protein kinase c.
UA107865C2 (en) Heterocyclic carboxamides
EA201300282A1 (en) DERIVATIVES OF TRIAZOLOPIRAZINE
EA024194B8 (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors
WO2012097093A3 (en) Novel wnt compositions and therapeutic uses of such compositions
WO2014058921A3 (en) Substituted pyrimidinyl kinase inhibitors
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2014060493A3 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
WO2012017321A3 (en) Treatment for dyslipidemia
WO2013054147A3 (en) Erlotinib salts
MX359399B (en) 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS.
WO2013155465A8 (en) Substituted xanthine derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12826647

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: A201404939

Country of ref document: UA

REEP Request for entry into the european phase

Ref document number: 2012826647

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012826647

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201490773

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014008733

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014008733

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140410